128 related articles for article (PubMed ID: 33193410)
1. Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method.
Toh ZQ; He L; Chen C; Huang A; Russell FM; Garland SM; Reyburn R; Ratu T; Tuivaga E; Frazer IH; Mulholland EK; Licciardi PV
Front Immunol; 2020; 11():585768. PubMed ID: 33193410
[TBL] [Abstract][Full Text] [Related]
2. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
[TBL] [Abstract][Full Text] [Related]
3. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies.
Quang C; Chung AW; Kemp TJ; Ratu T; Tuivaga E; Russell FM; Licciardi PV; Toh ZQ
J Med Virol; 2024 Jun; 96(6):e29732. PubMed ID: 38874202
[TBL] [Abstract][Full Text] [Related]
4. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
[TBL] [Abstract][Full Text] [Related]
5. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
[TBL] [Abstract][Full Text] [Related]
6. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
7. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
[TBL] [Abstract][Full Text] [Related]
9. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
[TBL] [Abstract][Full Text] [Related]
10. Multiplex immunoassay to measure antibody response to nine HPV vaccine types.
Panicker G; Rajbhandari I; Pathak HN; Brady AM; Unger ER
J Immunol Methods; 2021 Nov; 498():113136. PubMed ID: 34464605
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity correlation in cynomolgus monkeys between Luminex-based total IgG immunoassay and pseudovirion-based neutralization assay for a 14-valent recombinant human papillomavirus vaccine.
Bei L; Zhang X; Meng D; Gao S; Jia J; Zhao D; Luo C; Li X; Qiu H; Xie L
J Med Virol; 2022 Aug; 94(8):3946-3955. PubMed ID: 35388509
[TBL] [Abstract][Full Text] [Related]
12. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.
Longet S; Schiller JT; Bobst M; Jichlinski P; Nardelli-Haefliger D
J Virol; 2011 Dec; 85(24):13253-9. PubMed ID: 21976653
[TBL] [Abstract][Full Text] [Related]
13. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
[TBL] [Abstract][Full Text] [Related]
14. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
[TBL] [Abstract][Full Text] [Related]
15. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
16. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.
Wentzensen N; Rodriguez AC; Viscidi R; Herrero R; Hildesheim A; Ghosh A; Morales J; Wacholder S; Guillen D; Alfaro M; Safaeian M; Burk RD; Schiffman M
J Infect Dis; 2011 Jul; 204(1):94-102. PubMed ID: 21628663
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Lebacq M; van der Most R; Moris P; Giannini SL; Schuind A; Datta SK; Descamps D;
Hum Vaccin; 2011 Dec; 7(12):1359-73. PubMed ID: 22048172
[TBL] [Abstract][Full Text] [Related]
18. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.
Sehr P; Rubio I; Seitz H; Putzker K; Ribeiro-Müller L; Pawlita M; Müller M
PLoS One; 2013; 8(10):e75677. PubMed ID: 24124504
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
